152 related articles for article (PubMed ID: 15613909)
1. Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
Zell JA; Yoon EJ; Ignatius Ou SH; Hoefs JC; Chang JC
Anticancer Drugs; 2005 Jan; 16(1):83-5. PubMed ID: 15613909
[TBL] [Abstract][Full Text] [Related]
2. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
3. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma.
Visani G; Guiducci B; D'Adamo F; Mele A; Nicolini G; Leopardi G; Sparaventi G; Barulli S; Malerba L; Isidori A; Malagola M; Piccaluga PP
Leuk Lymphoma; 2005 Mar; 46(3):477-9. PubMed ID: 15621843
[No Abstract] [Full Text] [Related]
5. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
6. Fatal reactivation of hepatitis B after chemotherapy for lymphoma.
Dillon R; Hirschfield GM; Allison ME; Rege KP
BMJ; 2008 Jul; 337():a423. PubMed ID: 18595895
[No Abstract] [Full Text] [Related]
7. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
[TBL] [Abstract][Full Text] [Related]
8. Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus.
Ohmoto K; Tsuduki M; Yamamoto S
Am J Gastroenterol; 2003 May; 98(5):1215-6; author reply 1217. PubMed ID: 12809863
[No Abstract] [Full Text] [Related]
9. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.
Tsutsumi Y; Kawamura T; Saitoh S; Yamada M; Obara S; Miura T; Kanamori H; Tanaka J; Asaka M; Imamura M; Masauzi N
Leuk Lymphoma; 2004 Mar; 45(3):627-9. PubMed ID: 15160930
[TBL] [Abstract][Full Text] [Related]
10. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
Cheng AL
Blood; 1996 Feb; 87(3):1202. PubMed ID: 8562950
[No Abstract] [Full Text] [Related]
11. [A case of drug-induced liver injury caused by entecavir for treatment of hepatitis B virus reactivation during RCHOP in a patient with non-Hodgkin lymphoma].
Kondo M; Kitada N; Kobayashi M; Morita S; Yoshioka M; Tsuji T; Mori A; Okamoto T; Watari M
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1199-201. PubMed ID: 19620818
[TBL] [Abstract][Full Text] [Related]
12. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.
Lim KH; Yoon HI; Kang YA; Lee KW; Kim JH; Bang SM; Lee JH; Lee CT; Lee JS
Korean J Intern Med; 2010 Mar; 25(1):86-92. PubMed ID: 20195409
[TBL] [Abstract][Full Text] [Related]
13. [Icteric hepatitis in a patient with non-Hodgkin's lymphoma treated by rituximab-based chemotherapy].
Coppola N; Masiello A; Tonziello G; Macera M; Iodice V; Caprio N; Pasquale G
Infez Med; 2010 Jun; 18(2):127-31. PubMed ID: 20610938
[TBL] [Abstract][Full Text] [Related]
14. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.
Li X; Lin Q; Dong M; Wen JY; Wei L; Ma XK; Chen ZH; Wu XY
Leuk Lymphoma; 2010 Sep; 51(9):1678-85. PubMed ID: 20807095
[TBL] [Abstract][Full Text] [Related]
15. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.
Law JK; Ho JK; Hoskins PJ; Erb SR; Steinbrecher UP; Yoshida EM
Leuk Lymphoma; 2005 Jul; 46(7):1085-9. PubMed ID: 16019563
[TBL] [Abstract][Full Text] [Related]
16. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis.
Koo YX; Tan DS; Tan BH; Quek R; Tao M; Lim ST
J Clin Oncol; 2009 May; 27(15):2570-1; author reply 2571-2. PubMed ID: 19364951
[No Abstract] [Full Text] [Related]
18. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
Kilickap S; Yavuz B; Aksoy S; Sahiner L; Dincer M; Harputluoglu H; Erman M; Aytemir K; Tokgozoglu L; Barista I
Med Oncol; 2008; 25(4):437-42. PubMed ID: 18415035
[TBL] [Abstract][Full Text] [Related]
19. Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.
Stange MA; Tutarel O; Pischke S; Schneider A; Strassburg CP; Becker T; Barg-Hock H; Bastürk M; Wursthorn K; Cornberg M; Ott M; Greten TF; Manns MP; Wedemeyer H
Z Gastroenterol; 2010 Feb; 48(2):258-63. PubMed ID: 20127601
[TBL] [Abstract][Full Text] [Related]
20. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma.
Faggioli P; De Paschale M; Tocci A; Luoni M; Fava S; De Paoli A; Tosi A; Cassi E
Haematologica; 1997; 82(1):38-42. PubMed ID: 9107080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
